Winrevair Sotatercept CSRK 45mg Injection 1's

Winrevair 45 mg Injection is a prescription medicine used to treat pulmonary arterial hypertension (PAH), a serious condition in which the blood pressure in the arteries of the lungs becomes abnormally high. This condition can make it difficult for the heart to pump blood efficiently and may lead to heart complications over time.

Winrevair 45 mg Injection is a novel therapy that targets the root cause of abnormal blood vessel growth in the lungs. It is typically prescribed for adult patients who continue to experience symptoms despite receiving standard PAH treatments. Improving blood flow and reducing pressure in the pulmonary arteries, it helps enhance exercise capacity and overall quality of life.

• Treatment of pulmonary arterial hypertension (PAH) in adults
• Improvement in exercise ability and physical activity
• Reduction in symptoms such as breathlessness, fatigue, and chest discomfort
• Slowing the progression of PAH
• Lowering the risk of hospitalization due to worsening condition

It is often used alongside other PAH medications for better disease control.

Winrevair 45 mg Injection belongs to a class of medicines known as activin receptor signaling inhibitors.

In patients with PAH, there is an imbalance in certain cellular pathways that leads to narrowing and thickening of blood vessels in the lungs. This increases resistance to blood flow and raises blood pressure in the pulmonary arteries.

This medicine works by:

• Blocking abnormal activin signaling pathways
• Restoring balance between cell growth and repair
• Reducing excessive cell proliferation in lung blood vessels
• Improving the structure and function of pulmonary arteries

As a result, it lowers lung blood pressure and reduces strain on the heart.

Winrevair 45 mg Injection is administered as a subcutaneous injection under the supervision of a healthcare professional.

• Starting dose: 0.3 mg/kg of body weight
• Maintenance dose: May be increased to 0.7 mg/kg based on patient response
• Frequency: Once every 3 weeks

The dosage may be adjusted depending on laboratory results, especially hemoglobin and platelet levels. Patients should follow their doctor’s instructions strictly and should not change the dose on their own.

Common:

• Headache
• Nosebleeds
• Skin rash or redness
• Diarrhoea
• Dizziness
• Visible small blood vessels on the skin

These effects are usually mild and temporary.

Serious:

• Severe bleeding episodes
• Increased red blood cell count (erythrocytosis)
• Low platelet levels (thrombocytopenia)
• Risk of blood clots due to thickened blood

Seek immediate medical help if you experience:

• Unusual bleeding or bruising
• Black stools or blood in stools
• Severe headache or vision problems
• Sudden weakness or confusion 

Winrevair 45 mg Injection may interact with certain medicines, especially those affecting blood clotting.

Moderate Interaction:

Anticoagulants (blood thinners): May increase the risk of bleeding

Antiplatelet medicines: Can enhance bleeding tendency

Mild to Unknown Interaction:

Other pulmonary arterial hypertension medications

Herbal supplements that affect clotting mechanisms

Always inform your doctor about all medicines, supplements, and herbal products you are taking to avoid potential risks.

• Store in a refrigerator at 2°C to 8°C.
• Do not freeze.
• Keep in original packaging to protect from light.
• Use the prepared solution within 4 hours.
• Keep out of reach of children.

Do not use if the medicine appears discoloured or contains particles.

• Attend all scheduled appointments for blood tests to monitor hemoglobin and platelet levels.
• Inform your doctor immediately if you notice any signs of bleeding or bruising.
• Stay well hydrated and maintain a healthy lifestyle to support treatment outcomes.
• Avoid activities that may increase the risk of injury or bleeding.
• Do not miss scheduled doses, and follow the injection timeline strictly.
• Inform your doctor if you are planning pregnancy or undergoing any surgery.
• Keep track of any unusual symptoms and report them promptly.